Key result
Surgical and transcatheter aortic valve replacement resulted in significant improvements in quality of life at 12 months, with no significant difference between the two approaches (p=0.80).
Why the study?
The study was conducted to evaluate prospective outcomes in depression, quality of life, angina, and frailty among patients with aortic stenosis undergoing SAVR or TAVR.
Does surgical or transcatheter aortic valve replacement improve quality of life, depression, angina, and frailty in patients with aortic stenosis?
Cohort (n=300)
No
Does surgical or transcatheter aortic valve replacement improve quality of life, depression, angina, and frailty in patients with aortic stenosis?
p-value: p=0.80
Significant improvements in patient-reported outcome measures (quality of life, depression, angina) and frailty were observed by 3 months postoperatively in patients undergoing SAVR, TAVR, or CABG, with no significant difference in 12-month quality of life between SAVR and TAVR.
BACKGROUND: Our objective was to report on the prospective outcomes in the areas of depression, quality of life, angina, and frailty in SAVR and TAVR patients with aortic stenosis undergoing aortic valve intervention. METHODS: We recruited 300 patients across 3 groups (TAVR, SAVR, and CABG) over 12 months. Depression, quality of life, frailty, and angina were assessed followed by propensity score matching. RESULTS: Using logistical regression when all patient factors considered for all patients who had SAVR and TAVR, the only preoperative factors that impacted on 1 year mortality was hypertension and STS score. Quality of life improvements within each group over 12 months was significant (p value = 0.0001). Depression at 12 months between groups (p value = 0.0395) and within each group was significant (p value = 0.0073 for SAVR and 0.0001 for TAVR). Angina was most frequent in TAVR at 12 months in the QL (p = 0.0001), PL (p = 0.0007), and improvement was significant in the QL (SAVR p = 0.0010, TAVR p = 0.0001) and PL (SAVR p = 0.0002), TAVR p = 0.0007) domains in both groups. Frailty at 12 months improved in both groups, but was greatest in TAVR (p value = 0.00126). CONCLUSIONS: This 12 months follow up of cardiac surgical patients has revealed significant improvement in PROMs and frailty in all groups by 3 months postoperative regardless of surgical or transcatheter approach. Outcome measures of quality of life and frailty could be utilized as a measure of outcome more regularly in patients undergoing aortic valve surgery regardless of approach.
No takes yet. Share an insight, caveat, or question.
Surman et al. (2022) conducted a cohort in Aortic stenosis (n=300). Surgical and transcatheter aortic valve replacement vs. Coronary artery bypass grafting (CABG) was evaluated on Quality of life between SAVR and TAVR over a 12-month period (p=0.80). Surgical and transcatheter aortic valve replacement resulted in significant improvements in quality of life at 12 months, with no significant difference between the two approaches (p=0.80).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: